Skip to main content
main-content

Rheumatology

Latest articles

21-04-2017 | Rheumatology | News | Article

Support for mycophenolate therapy in patients with SSc-related interstitial lung disease

Mycophenolate mofetil is associated with improvements in lung function compared with placebo among patients with systemic sclerosis (SSc)-associated interstitial lung disease, study results suggest.

Source:

Arthritis Rheumatol 2017; Advance online publication

20-04-2017 | Rheumatology | News | Article

Tocilizumab efficacy maintained for up to 2 years in RA patients

Patients with early rheumatoid arthritis who are treated with tocilizumab maintain the clinical benefits during their second year of treatment, analysis of phase III study data suggests.

Source:

Ann Rheum Dis 2017; Advance online publication

19-04-2017 | Rheumatology | News | Article

Celecoxib linked to reduced GI bleeding risk in patients with arthritis, cardiothrombotic disease

Results of the CONCERN trial suggest that celecoxib is associated with a lower risk for recurrent upper gastrointestinal bleeding than naproxen among patients with arthritis and cardiothrombotic diseases treated concomitantly with aspirin and non-steroidal anti-inflammatory drugs.

Source:

Lancet 2017; Advance online publication

13-04-2017 | Rheumatology | News | Article

News in brief

Potential role for omega-3 PUFAs in RA non-inflammatory pain suppression

Study results suggest that dietary intake of omega-3 polyunsaturated fatty acids is inversely associated with unacceptable and refractory pain, but not inflammatory pain, in patients with rheumatoid arthritis (RA).

11-04-2017 | Rheumatology | News | Article

Pedometer-based intervention reduces fatigue in RA patients

Provision of pedometers could improve activity levels and reduce fatigue among patients with rheumatoid arthritis, results of a randomized trial suggest.

Source:

Arthritis Care Res 2017; Advance online publication

07-04-2017 | Rheumatology | News | Article

Immune cell analysis could predict biological DMARD response in RA patients

Different biological disease-modifying antirheumatic drugs induce distinct changes in immune cell subsets among patients with rheumatoid arthritis, study results suggest.

Source:

Rheumatology 2017; Advance online publication

03-04-2017 | Rheumatology | News | Article

Omega-3 PUFAs may have limited benefits in PsA

News in brief

Trial results suggest that omega-3 polyunsaturated fatty acid supplementation has no effect on disease activity but could reduce requirement for pain relief in patients with psoriatic arthritis.

30-03-2017 | Rheumatology | News | Article

Knee replacement practice in OA patients questioned

Results of a study published in The BMJ suggest that total knee replacement has “minimal effects” on quality of life among patients with knee osteoarthritis, and restricting surgery to those with more severe disease would improve cost-effectiveness of the procedure in the USA.

Source:

BMJ 2017; 356: j1131

30-03-2017 | Rheumatology | News | Article

Anticollagen antibodies predict favorable prognosis in RA

Antifibrillar collagen type II antibodies are associated with a favorable inflammatory outcome among patients with rheumatoid arthritis, researchers report.

Source:

Ann Rheum Dis 2017; Advance online publication

28-03-2017 | Rheumatology | News | Article

Support for allopurinol dose escalation in patients with gout

 Escalation of allopurinol to above creatinine clearance based doses is effective for achieving target serum urate levels in patients with gout, study findings suggest.

Source:

Ann Rheum Dis 2017; Advance online publication

27-03-2017 | Rheumatology | News | Article

Rituximab falls short in Sjögren's syndrome trial

Treatment with two courses of rituximab does not reduce fatigue or oral dryness among patients with primary Sjögren's syndrome, results of the TRACTISS trial suggest.

Source:

Arthritis Rheumatol 2017; Advance online publication

24-03-2017 | Rheumatology | News | Article

Adalimumab discontinuation ‘feasible’ in early RA patients

The majority of patients with early rheumatoid arthritis maintain low disease activity for up to 3 years after discontinuing adalimumab therapy, Japanese researchers report.

Source:

Arthritis Res Ther 2017; 19: 56

20-02-2017 | Rheumatology | News | Article

Baricitinib shows promise in patients with RA

Results of the RA-BEAM trial suggest that baricitinib may improve clinical outcomes relative to placebo or adalimumab among patients with active rheumatoid arthritis who have an inadequate response to methotrexate.

Source:

N Engl J Med 2017; 376: 652–662

02-02-2017 | Pulmonary hypertension | News | Article

Ambrisentan–tadalafil combination beneficial in CTD-associated PAH

A post-hoc subgroup analysis of the AMBITION trial suggests that the benefits of ambrisentan and tadalafil combination therapy extend to patients with connective tissue disease-associated pulmonary arterial hypertension.

Source:

Ann Rheum Dis 2016; Advance online publication

17-01-2017 | Pulmonary hypertension | News | Article

NT-proBNP promising biomarker for SSc-PAH

N-terminal pro-B-type natriuretic peptide may be more accurate than B-type natriuretic peptide for detecting and monitoring pulmonary arterial hypertension in patients with systemic sclerosis, study findings suggest.

Source:

Clin Exp Rheumatol 2016; Advance online publication

22-08-2016 | Lymphoma | News | Article

News in brief

RA-related lymphoma risk not attributable to TNF inhibitors

In patients with rheumatoid arthritis, medium-term treatment with tumour necrosis factor inhibitors does not increase the risk of developing lymphoma over and above the background risk associated with RA.

15-08-2016 | Oncology | News | Article

RA diagnosis negatively affects cancer survival

Among elderly patients who develop cancer, the risk of mortality is higher for those with versus without rheumatoid arthritis, finds a US population-based study.

Source:

Arthritis Care Res 2016; Advance online publication

29-06-2016 | Oncology | News | Article

Editor's pick

Immunotherapy-treated cancer patients may develop rheumatic disorders

Oncologists need to be aware of the potential for rheumatological diseases in patients with cancer following treatment with immune checkpoint inhibitors, say US investigators.

Source:

Ann Rheum Dis 2016; Advance online publication

15-06-2016 | Pulmonary hypertension | News | Article

Potential non-invasive screening biomarker for SSc-PAH

Serum asymmetric dimethylarginine may be an effective non-invasive screening biomarker for systemic sclerosis-related pulmonary arterial hypertension, study findings indicate.

Source:

Clin Exp Rheumatol 2016; Advance online publication

08-06-2016 | Pulmonary hypertension | News | Article

Reduced RV functional reserve may explain poor SSc-PAH outcomes

Patients who develop pulmonary arterial hypertension as a consequence of systemic sclerosis have poorer right ventricular functional reserve than those with idiopathic disease, research published in Circulation shows.

Source:

Circulation 2016; Advance online publication

image credits